Overview

Erythropoietin Protects Very Preterm Infants Against Necrotizing Enterocolitis

Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effect of repeated low-dose erythropoietin (EPO) treatment on necrotizing enterocolitis (NEC) in very preterm infants. Half of participants will receive EPO, while the other half will receive a placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Zhengzhou University
Collaborators:
Göteborg University
The First Affiliated Hospital of Zhengzhou University
Women and Children Health Care Center of Luoyang, China
Zhengzhou Children's Hospital, China
Treatments:
Epoetin Alfa